Abaloparatide
Also called Tymlos, BA058
Subcutaneous (under the skin)Product label
Research reference
Product label
Tymlos ready-filled pen
80 mcg once daily using the supplied pen
Use beyond 2 lifetime years is not recommended in the label
Tymlos product label ↗When results may show
- When change was measured
- Bone health and calcium-related safety guide review. A 30-day pen supply is not an instruction to stop after a month.
- When to assess
- Use beyond 2 lifetime years is not recommended in the label
- Conditions and limitations
- Specified adults with osteoporosis at high fracture risk. Product-specific daily schedule, not a powder-vial protocol. First administrations need precautions for dizziness/low blood pressure.
- When to stop
- Use the exact product's clinical monitoring and stopping instructions. A supply interval is not a stop date; severe or persistent reactions need prompt clinical review.
Sources: Tymlos product label
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Vial arithmetic
Published research contexts for Abaloparatide describe 80–80 mcg per administration. Descriptive only, not a recommendation.
Modelled level — every day
1× is the peak after a single dose.
- Steady-state peak
- 0.99× single dose
- Time to steady state
- 9hours
- Administrations
- 7/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Tymlos product labelProduct-specific daily schedule, not a powder-vial protocol. First administrations need precautions for dizziness/low blood pressure.
Next steps
Abaloparatide beginner guideOpen Abaloparatide planning worksheetEstimate Abaloparatide vial costTrack Abaloparatide notes